Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy. Lerociclib plus fulvestrant demonstrated a ...

Experts discuss how, nearly half of patients diagnoses with HER-2 positive metastatic brain cancer do develop brain metastasis. It is thought that larger molecule treatments such as the monoclonal ant ...

The WOLVERINE meta-analysis reinforces the role of MDT in delaying disease progression in patients with oligometastatic ...

Seth Eisenberg, ASN, RN, OCN, BMTCN discussed the results of a real-world trial of Splashblocker, a toilet seat cover ...

Evaluation of nemvaleukin for platinum-resistant ovarian cancer will be terminated based on OS data from an interim analysis ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Debriefing after patient loss, supporting patients at the end of life, and finding outlets outside of work can help oncology nurses avoid burnout.

BC, OCN, explained that comprehensive disease and treatment education are essential to adherence for patients with breast ...

Experts discuss how to facilitate open communication among the patient, caregivers, and the multidisciplinary team to ensure comprehensive care and alignment on treatment goals.

Experts discuss how to manage fatigue, abdominal pain, and other treatment-related symptoms to maintain or improve quality of life for patients undergoing HER2-targeted therapy and share strategies ...

The FDA has approved neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab after radical cystectomy in MIBC.

The presence of biomarkers, even in small amounts, can shape the course of treatment for a patient, says Andy Guinigundo, MSN, RN, CNP, ANP-BC.